BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26270123)

  • 1. Treatment Compliance and Outcomes for Women With Locoregionally Advanced Cervical Cancer Treated in a Safety Net Health System.
    Hsieh GL; Linesch S; Sajjad A; Macdonald A; Bonnen M; Anderson ML; Ludwig MS
    Int J Gynecol Cancer; 2015 Nov; 25(9):1669-76. PubMed ID: 26270123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.
    Tharavichitkul E; Lorvidhaya V; Kamnerdsupaphon P; Sukthomya V; Chakrabandhu S; Klunklin P; Onchan W; Supawongwattana B; Pukanhaphan N; Galalae R; Chitapanarux I
    BMC Cancer; 2016 Jul; 16():501. PubMed ID: 27435245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
    Kim YS; Shin SS; Nam JH; Kim YT; Kim YM; Kim JH; Choi EK
    Gynecol Oncol; 2008 Jan; 108(1):195-200. PubMed ID: 17963825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.
    Castelnau-Marchand P; Chargari C; Maroun P; Dumas I; Del Campo ER; Cao K; Petit C; Martinetti F; Tafo-Guemnie A; Lefkopoulos D; Morice P; Haie-Meder C; Mazeron R
    Gynecol Oncol; 2015 Nov; 139(2):288-94. PubMed ID: 26364808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
    Martínez-Monge R; Gaztañaga M; Aramendía JM; Cambeiro M; Arbea L; Espinós J; Aristu JJ; Jurado M
    Int J Gynecol Cancer; 2010 Jan; 20(1):133-40. PubMed ID: 20130514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
    Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
    Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Metabolic Parameters as Prognostic Factors During Concomitant Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Krhili S; Muratet JP; Roche S; Pointreau Y; Yossi S; Septans AL; Denis F
    Am J Clin Oncol; 2017 Jun; 40(3):250-255. PubMed ID: 27028351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
    Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
    Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer.
    Tangsiriwatthana T; Chumworathayi B; Yuenyao P; Luanratanakorn S; Pattamadilok J
    Radiat Med; 2007 Dec; 25(10):502-10. PubMed ID: 18085400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen?
    Sebastião AM; da Silva Rocha LS; Gimenez RD; de Barros LA; Fukushima JT; da Silva SC; da Costa Miranda V; de Souza Caires IQ; de Freitas D; Filho EA; Diz Mdel P
    Eur J Obstet Gynecol Reprod Biol; 2016 Jun; 201():161-5. PubMed ID: 27137353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial.
    Köhler C; Mustea A; Marnitz S; Schneider A; Chiantera V; Ulrich U; Scharf JP; Martus P; Vieira MA; Tsunoda A
    Am J Obstet Gynecol; 2015 Oct; 213(4):503.e1-7. PubMed ID: 25986030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive chemoradiotherapy for cervical cancer: A 11-year population-based study.
    Kalampokas E; Macdonald G; Young H; Bednarek A; Kennedy AM; Cairns M; Parkin DE
    Eur J Cancer Care (Engl); 2020 May; 29(3):e13223. PubMed ID: 31944444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.